Coloxyl Infant Drops

Newborn use only

Alert	Do not use in infants <2000 g without the consent of the neonatologist or paediatrician in-charge.
Aicit	(ANMF consensus)
	There are no published trials in neonates despite its usage.
	Contains ethanol 3.6% w/w.
Indication	Constipation
Action	Contains poloxamer.
	Poloxamer draws water into the stool, making it softer and easier to pass. Onset of effect is 2-3 days.
Drug type	Osmotic laxative
Trade name	Coloxyl Infant Drops
Presentation	Poloxamer 100 mg/mL oral drops (30 mL)
Dose	0.3 mL three times daily.
D 030	*Do not use in infants <2000 g without the consent of the neonatologist or paediatrician in-charge.
	(ANMF consensus)
Dose adjustment	No information
Maximum dose	THE INITIALISM
Total cumulative	
dose	
Route	Oral
Preparation	No preparation required
Administration	Administer undiluted, preferably mixed with feeds
Monitoring	Loose stools, abdominal cramps
Contraindications	Gastrointestinal obstruction
Precautions	Persistent symptoms, prolonged use, dehydration - ensure adequate fluid intake. (3)
Drug interactions	
Adverse reactions	Loose stools, dehydration, abdominal discomfort.
	Chronic misuse of laxatives may result in electrolyte imbalance.
	Loss of effectiveness with prolonged usage.
Compatibility	Not applicable
Incompatibility	Not applicable
Stability	As per the manufacturer's recommendations
Storage	Store below 30°C
Excipients	Ethanol 3.6% w/w, glycerol, sorbic acid, purified water, caramel and chocolate flavours
Special comments	
Evidence	Background
	Osmotic laxatives draw water into the stool, resulting in softer stools and more frequent, easier to
	pass bowel movements. Some commonly used laxatives in children are polyethylene glycol (PEG),
	lactulose and milk of magnesia. ⁽¹⁾
	Efficacy
	There are no published trials evaluating the efficacy of poloxamer for constipation in neonates.
	Safety
	Anecdotal experience suggests that poloxamer is well tolerated in infants. A nationwide matched
	cohort study of Taiwanese children found an association between early life laxative exposure within
	the first 6 months of life and subsequent allergic disease development in all subgroups of children,
¥	including those born to mothers without allergic diseases or prenatal laxative use. (2) In this study
	there was no specific reference to poloxamer. Prolonged usage of laxative use may result in loss of
	effectiveness.
	Pharmacokinetics
	Poloxamer is not absorbed by the gut.
	Pharmacodynamics Transfer of the control of the con
	Poloxamer draws water into the stool, making it softer and easier to pass. This softening process
	happens gradually and can take 2 to 3 days. (3)
Practice points	The second secon

Coloxyl Infant Drops

Newborn use only

References	1. Gordon M, MacDonald JK, Parker CE, Akobeng AK, Thomas AG. Osmotic and stimulant laxatives for the management of childhood constipation. Cochrane Database of Systematic Reviews. 2016(8):CD009118.
	2. Lin TL, Wu CY, Fan YH, Chang YL, Ho HJ, Chen YJ. Association between early life laxative exposure and risk of allergic diseases A nationwide matched cohort study. Ann Allergy Asthma Immunol. 2022;128(3):291-8.e3.
	3. Coloxyl Infant Drops. Product info. MIMS online. Accessed on 1 June 2022.

VERSION/NUMBER	DATE
Original 1.0	23/06/2022
REVIEW	23/06/2027

Authors Contribution

Author/s	Srinivas Bolisetty
Evidence Review	Srinivas Bolisetty
Expert review	Michael Stormon; Usha Krishnan
Nursing Review	Eszter Jozsa, Sarah Neale, Priya Govindaswamy
Pharmacy Review	Mohammad Irfan Azeem, Thao Tran
ANMF Group contributors	Nilkant Phad, Bhavesh Mehta, John Sinn, Helen Huynh, Cindy Chen, Michelle Jenkins, Rebecca Barzegar, Ian Callander
Final editing	Thao Tran
Electronic version	Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty

